NP1192

NP1192 is a potent, selective PROTAC NAT10 degrader that depletes NAT10 protein and inhibits ac4C modification in cancer cells. NP1192 demonstrates dual inhibition of hypoxia-driven glycolysis and immunosuppression via NAT10/HIF-1α/PD-L1 axis disruption, achieving superior antitumor efficacy and synergizing with anti-PD-L1 both in vitro and in vivo. NP1192 can be used for ovarian, cervical, and glioblastoma cancer research. (Blue: CRBN ligand (HY-148834) ; Black: linker; Pink: NAT10 ligand (HY-16706) ) [1].

Product Specifications

CAS Number

[2966791-41-1]

UNSPSC

12352005

Target

HIF/HIF Prolyl-Hydroxylase; Histone Acetyltransferase; PD-1/PD-L1; PROTACs; PTEN

Related Pathways

Epigenetics; Immunology/Inflammation; Metabolic Enzyme/Protease; PI3K/Akt/mTOR; PROTAC

Field of Research

Cancer; Metabolic Disease; Inflammation/Immunology

Smiles

N#CC1=CC=C(C=C1)C2=CSC(N(/N=C3CCCC/3)CCCCCCC(N4CCN(CC4)C5=C6C(N(C(C6=CC=C5)=O)C7CCC(NC7=O)=O)=O)=O)=N2

Molecular Formula

C39H42N8O5S

Molecular Weight

734.87

References & Citations

[1]Ao, K., et al. Targeted NAT10 Degradation by PROTAC NP1192 Suppresses Hypoxia-Adaptive Glycolysis and Reinvigorates CD8+ Effector T-Cell Function for Synergistic Cancer Immunotherapy. ACS Central Science. 2025.